Vericel Earnings Call Signals Accelerating Growth and Margins

Vericel Corporation ((VCEL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Vericel Corporation’s latest earnings call painted a distinctly upbeat picture, with management highlighting record revenue, accelerating growth in its core MACI franchise, surging burn care sales, and a sharp step-up in profitability and cash generation. While executives acknowledged some uncertainties around government contracts, conversion metrics, and macro risks, they emphasized that operational momentum and financial strength are firmly on their side.

Record Revenue and Strong Year-Over-Year Growth

Vericel delivered total revenue of $68.4 million in the first quarter of 2026, a 30% increase from the prior year and well ahead of its own guidance. Management underscored that this performance sets a high bar for the rest of the year and reflects broad-based strength across its portfolio rather than a single one-off driver.

MACI Franchise Delivers Sustained High Growth

MACI revenue reached $56.4 million in the quarter, up 22% year over year and marking the fourth straight quarter of at least 20% growth. The trailing four-quarter MACI growth rate accelerated to 23%, and guidance for the second quarter implies another step up to roughly $62.5 million to $63.5 million in sales.

Burn Care Momentum and Impact of BARDA Award

Burn care revenue surpassed $12 million, growing more than 90% year over year, driven by $10.9 million from Epicel and $1.1 million from NexoBrid, with NexoBrid up about 60% versus the prior quarter. The company also announced a major BARDA award of up to $197 million, including a $35 million base contract and expected NexoBrid procurement revenue of roughly $5 million to $6 million in the back half of 2026.

Margin Expansion and Profitability Gains

Vericel’s gross margin expanded by more than 300 basis points to 72% in the first quarter, reflecting improved scale and mix. Adjusted EBITDA margin nearly doubled to 14%, with adjusted EBITDA of about $9.6 million, which management noted was almost triple the prior-year level.

Robust Cash Generation and Balance Sheet Strength

Operating cash flow reached $16.4 million in the quarter, while free cash flow came in at $15.1 million, marking the third consecutive period with at least $12 million of free cash generation. The company ended the quarter with approximately $211 million in cash and investments, nearly $50 million higher than a year ago, giving it ample financial flexibility.

Sales Force Expansion Fuels Commercial Execution

The first full quarter with an expanded MACI sales force produced record levels of biopsies, implants, and active biopsy or implanting surgeons. Management also highlighted rising implants and biopsies per surgeon and better biopsy-to-implant pull-through, particularly in newly opened territories, indicating the expansion is already paying off.

Early Clinical Signals from MACI Arthro

Investigators reported early case series data for MACI Arthro showing reduced post-operative pain, better range of motion, and quicker time to full weight bearing. These initial results have been accepted for publication, and the company is building a registry to collect longer-term outcomes data that could support broader adoption and coverage.

Manufacturing Milestone and International Expansion Pathway

The FDA approved commercial MACI manufacturing at Vericel’s new Burlington facility, meaningfully expanding capacity and operational resilience. This site is also central to the company’s international strategy, enabling a planned marketing application in the U.K. later in 2026, with a potential launch in that market in 2027.

Raised Full-Year 2026 Guidance

Vericel raised its total 2026 revenue outlook by $10 million to a range of $326 million to $336 million, implying about 20% growth at the midpoint, on the back of its Q1 beat and strong momentum in MACI and burn care. The company lifted MACI guidance to $282 million to $288 million and burn care to $44 million to $48 million, while reiterating profitability targets including a roughly 75% gross margin and about a 27% adjusted EBITDA margin for the year.

BARDA Revenue Timing and Uncertainty

Management emphasized that only part of the BARDA award is currently contracted, with the $35 million base and optional components tied to future procurement, development, and formulation work. While the initial procurement revenue of about $5 million to $6 million expected in the second half of 2026 is modest, investors were reminded that the larger value of the award will accrue over multiple years and remains contingent.

Reliance on Biopsy-to-Implant Conversion

Executives reiterated that sustained MACI growth depends heavily on maintaining or improving the rate at which biopsies convert into implants, a key internal metric. While current conversion trends are stable and even contributing to upside, management cautioned that a reversal in this measure could pose a risk to the growth trajectory.

Near-Term Investment Drag on Margins

The company acknowledged that ramping the Burlington facility, expanding the MACI sales force, and funding a MACI ankle trial and other life-cycle projects will pressure margins in the near term. Second-quarter guidance calls for gross margin around 72% and an adjusted EBITDA margin near 18%, below full-year targets, underscoring that short-term variability is part of its investment plan.

Evidence and Adoption Curve for MACI Arthro

MACI Arthro gained approval based on human factors rather than large clinical outcome trials, so broader adoption and payer coverage will depend on accumulating prospective, peer-reviewed results. Management views the early data as encouraging but acknowledged that meaningful commercial traction will likely lag until more robust evidence is generated and published.

Macro and Access Risks in Orthopedic Procedures

Analysts pressed the company on broader orthopedic procedure risks such as payer dynamics and potential changes in coverage or patient affordability. Vericel has not built a meaningful slowdown into its guidance but recognized that external macro and access factors could influence procedure volumes and represents a watch point for investors.

Competitive Landscape and Patient Segmentation

Management addressed questions about Agili‑C, a competing product aimed more at older patients with osteoarthritis than the typical MACI candidate. While Vericel does not expect a major overlap today, it is keeping a close eye on how competitive segmentation evolves and how it might shape future positioning and growth.

Forward-Looking Guidance and Outlook

The company’s updated 2026 guidance embeds mid-teens to high-teens margin expansion and sustained high-teens to low-20s top-line growth, supported by MACI demand, burn care momentum, and modest BARDA procurement contribution starting in the third quarter. With strong cash reserves, management signaled confidence in funding its commercial, clinical, and capacity investments while still delivering rising profitability.

Vericel’s earnings call underscored a business firing on multiple cylinders, from accelerating MACI sales to a rapidly growing burn care franchise and expanding margins. While investors must weigh conversion metrics, BARDA timing, and macro risks, the company’s upgraded outlook and solid balance sheet suggest it is well positioned to extend its growth story in the quarters ahead.